Answers are grounded in this paper and cite their sources.
Recently, Tartaglia et al (2005) reported a 4·4% prevalence of PTPN11 mutations in childhood acute myeloid leukaemia (AML) patients included in the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials with a significantly increased prevalence in French-American-British (FAB) M5 (18%). In addition, a USA-based series also detected PTPN11 mutation in 4% of paediatric AML samples, and again the prevalence of PTPN11 mutations was significantly higher in FAB M5 compared with non-FAB M5 cases (12% vs. 2·5%, P = 0·016) (Loh et al, 2004). We previously reported that in a northern European cohort (the Netherlands and Germany) of 150 paediatric AML samples, 40% harboured a mutation in either KIT, RAS or a FLT3/ITD.(Goemans et al, 2005) Notably, this series showed a low frequency of these mutations in FAB M5 compared to non-FAB M5 AML (10% vs. 45%, P = 0·011). We therefore hypothesised that PTPN11 might be involved in the development of FAB M5 AML and investigated the prevalence of PTPN11 mutations in this patient cohort. Moreover, we enriched this cohort with another 24 paediatric FAB M5 AML patients, for a total of 55 M5 cases. This is the largest FAB M5 cohort studied for PTPN11 mutations reported to date. Patients were treated on intensive cytarabine/anthracycline-based protocols in the Netherlands (Dutch Childhood Oncology Group) and Germany (Berlin-Frankfürt-Münster Study Group for acute myeloid leukaemia) between February 1990 and September 2003 (Goemans et al, 2005). Both study groups performed central review of diagnosis and classification of patients. All 174 samples were genotyped for mutations in PTPN11 exons 3 and 13 using D-HPLC and direct sequencing, as previously described (Tartaglia et al, 2002). Mutations affecting exons 3 and 13 were detected in seven and three samples respectively (Table I). There were no differences in age, sex or white blood cell count at diagnosis between patients with and without a PTPN11 mutation. In one patient we detected both an NRAS and a PTPN11 mutation. Only 4/10 PTPN11 mutated cases were diagnosed with FAB M5 AML. The other FAB-types were FAB M2 (2/39), M4 (3/42) and M6 (1/4). The PTPN11 mutation prevalence did not differ significantly between FAB M5 and non-FAB M5 cohorts (7·3% vs. 5·0%, P = 0·73). Thus, the prevalence of PTPN11 mutations in FAB M5 in this cohort was lower than in the Italian cohort, although this difference was not statistically significant (chi-square P = 0·11). We cannot exclude that the observed difference is the result of chance, and therefore these data need to be validated in a larger prospective cohort of patients. Methodological differences in mutation detection are unlikely to account for this difference, as the same techniques were used in both studies. Eighteen M5 samples were PTPN11 genotyped twice in two different laboratories, including the laboratory in which the Italian AML samples were studied, with identical results. We hypothesise that this difference might be caused by a differential genetic susceptibility for specific AML subtypes. A similar phenomenon has been documented for the prevalence of acute promyelocytic leukaemia (APL). The prevalence of APL in the Mediterranean countries (Italy and Spain) and Hispanics is higher compared with northern European countries, such as Germany, and non-Hispanic whites in the USA (Douer, 2003). Unfortunately, we have no data on the ethnic background of our patients. In conclusion, we detected a PTPN11 mutation in 5·4% of paediatric AML cases but, in contrast to other reports, the prevalence was not increased in FAB M5 AML. One explanation for this difference could lie in the different ethnic backgrounds of the patients studied. Future studies should consider possible differences in prevalence of oncogenic mutations between ethnic groups. The prevalence of mutations in FAB M5 still is low (26%) compared with non-FAB M5 AML (50%), and we continue to search for novel mutations in this AML subgroup.
No takes yet. Share an insight, caveat, or question.
Goemans et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: